Birchview Capital, LP Axsome Therapeutics, Inc. Transaction History
Birchview Capital, LP
- $95 Million
- Q2 2025
A detailed history of Birchview Capital, LP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 6,000 shares of AXSM stock, worth $789,600. This represents 0.66% of its overall portfolio holdings.
Number of Shares
6,000
Previous 6,000
-0.0%
Holding current value
$789,600
Previous $699,000
10.44%
% of portfolio
0.66%
Previous 0.63%
Shares
3 transactions
Others Institutions Holding AXSM
# of Institutions
407Shares Held
37.4MCall Options Held
507KPut Options Held
541K-
Vanguard Group Inc Valley Forge, PA3.95MShares$519 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$434 Million0.01% of portfolio
-
Bvf Inc San Francisco, CA1.69MShares$222 Million6.93% of portfolio
-
Rtw Investments, LP New York, NY1.52MShares$200 Million2.43% of portfolio
-
Macquarie Group LTD Australia, C31.14MShares$150 Million0.15% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $5.64B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...